Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary.
Hungarian Academy of Sciences, Premium Postdoctoral Research Programme, Nádor u. 7, H-1051, Budapest, Hungary.
Br J Dermatol. 2018 Nov;179(5):1102-1108. doi: 10.1111/bjd.16927. Epub 2018 Sep 19.
'Not relevant' responses (NRRs) on the Dermatology Life Quality Index (DLQI) may occur in up to 40% of patients with psoriasis. As these responses are scored as the item of the questionnaire having no impact on the patients' lives at all, it is more difficult for these patients to fulfil the DLQI > 10 criterion required by clinical guidelines to become candidates for systemic treatment including biologics.
We propose a new scoring system for the DLQI that corrects for the bias in the NRR option and test its construct validity in a sample of patients with psoriasis.
Data from 242 patients (104 of whom marked at least one NRR) from two earlier cross-sectional surveys were reanalysed. For each patient, the DLQI score was calculated in two ways: (i) according to the original scoring and (ii) by applying a new scoring formula (DLQI-R) that adjusts the total score for the number of NRRs. The construct validity of the DLQI-R was tested against the Psoriasis Area and Severity Index (PASI) and EQ-5D-3L.
The mean DLQI and DLQI-R scores were 9·99 ± 7·52 and 11·0 ± 8·02, respectively. The DLQI-R allowed eight more patients (3·3%) to achieve the 'PASI > 10 and DLQI > 10' threshold. The results were robust when limiting the maximum number of NRRs allowed to two or three. Compared with the DLQI, DLQI-R correlated slightly better with PASI (r = 0·59 vs. 0·57) and EQ-5D-3L index scores (r = -0·58 vs. -0·54).
The DLQI-R seems to be a valid scoring system for avoiding the bias in the NRR option and can help to improve patients' access to biologics.
在接受银屑病评估的患者中,高达 40%的患者可能会对皮肤病生活质量指数(DLQI)中的“无相关”(NRR)答案作出应答。由于这些答案被视为问卷中对患者生活完全没有影响的项目,因此对于这些患者来说,满足临床指南中要求的 DLQI>10 这一标准,以成为接受包括生物制剂在内的全身治疗的候选者变得更加困难。
我们提出了一种新的 DLQI 评分系统,以纠正 NRR 选项的偏差,并在银屑病患者样本中测试其结构有效性。
对来自两项先前横断面研究的 242 名患者(其中 104 名患者至少标记了一个 NRR)的数据进行重新分析。对每位患者,使用两种方法计算 DLQI 评分:(i)根据原始评分方法,(ii)应用新的评分公式(DLQI-R),对总分进行 NRR 数量的调整。通过与银屑病面积和严重性指数(PASI)和 EQ-5D-3L 进行对比,来测试 DLQI-R 的结构有效性。
平均 DLQI 和 DLQI-R 评分分别为 9.99±7.52 和 11.0±8.02。DLQI-R 允许另外 8 名患者(3.3%)达到“PASI>10 和 DLQI>10”的阈值。当限制允许的 NRR 数量最多为 2 或 3 时,结果仍然是稳健的。与 DLQI 相比,DLQI-R 与 PASI(r=0.59 对 0.57)和 EQ-5D-3L 指数评分(r=-0.58 对-0.54)的相关性略好。
DLQI-R 似乎是一种有效的评分系统,可以避免 NRR 选项的偏差,并有助于改善患者获得生物制剂的机会。